N1-(4-chloro)benzyl biguanide hydrochloride | 4751-79-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N1-(4-chloro)benzyl biguanide hydrochloride
• 英文别名: 1-(4-chlorobenzyl)biguanide hydrochloride；4-Chlorobenzylbiguanide hydrochloride；[amino-(diaminomethylideneamino)methylidene]-[(4-chlorophenyl)methyl]azanium;chloride
• CAS: 4751-79-5
• 化学式: C₉H₁₂ClN₅*ClH
• 分子量: 262.142
• InChiKey: XGGQCDGSBPCBDO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.85
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  103
• 氢给体数：
  4
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  环丙甲基酮 、 N1-(4-chloro)benzyl biguanide hydrochloride 在 盐酸 、 原甲酸三乙酯 作用下， 以 甲醇 、 水 为溶剂， 以28%的产率得到4,6-diamino-1-(4'-chlorobenzyl)-2-cyclopropyl-2-methyl-1,2-dihydro-1,3,5-triazine hydrochloride
  参考文献：
  名称：

  Synthesis and antimicrobial activity of N1-benzyl or N1-benzyloxy-1,6-dihydro-1,3,5-triazine-2,4-diamines

  摘要：

  The emergence and spread of multidrug-resistant strains of Staphylococcus aureus and Mycobacterium tuberculosis are generating a threat to public health worldwide. In the current study, a series of N-1-benzyl and N-1-benzyloxy-1,6-dihydro-1,3,5-triazine-2,4-diamine derivatives were synthesized and investigated for their antimicrobial activity against S. aureus, and Mycobacterium smegmatis which is taxonomically related to M. tuberculosis. Most of the compounds exhibited good activity against M. smegmatis as determined by comparison of diameters of the zone of inhibition of test compounds and standard antibiotics. Compound 7o showed potent antimycobacterial activity against M. smegmatis without mammalian DHFR inhibition liability. The results from this study indicate that 1-benzyl derivatives of 1,6-dihydro-1,3,5-triazine-2,4-diamines may be used as lead compounds for the discovery of antimycobacterial agents. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.125
• 作为产物：
  描述：

  对氯苄胺 在 盐酸 作用下， 以 乙醚 为溶剂， 生成 N1-(4-chloro)benzyl biguanide hydrochloride
  参考文献：
  名称：

  Synthesis and antimicrobial activity of N1-benzyl or N1-benzyloxy-1,6-dihydro-1,3,5-triazine-2,4-diamines

  摘要：

  The emergence and spread of multidrug-resistant strains of Staphylococcus aureus and Mycobacterium tuberculosis are generating a threat to public health worldwide. In the current study, a series of N-1-benzyl and N-1-benzyloxy-1,6-dihydro-1,3,5-triazine-2,4-diamine derivatives were synthesized and investigated for their antimicrobial activity against S. aureus, and Mycobacterium smegmatis which is taxonomically related to M. tuberculosis. Most of the compounds exhibited good activity against M. smegmatis as determined by comparison of diameters of the zone of inhibition of test compounds and standard antibiotics. Compound 7o showed potent antimycobacterial activity against M. smegmatis without mammalian DHFR inhibition liability. The results from this study indicate that 1-benzyl derivatives of 1,6-dihydro-1,3,5-triazine-2,4-diamines may be used as lead compounds for the discovery of antimycobacterial agents. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.125

文献信息

• Synthesis and in vitro evaluation of 2,4-diamino-1,3,5-triazine derivatives as neuronal voltage-gated sodium channel blockers
  作者：Xiang Ma、Thong-Yuen Poon、Peter Tsun Hon Wong、Wai-Keung Chui

  DOI：10.1016/j.bmcl.2009.08.052

  日期：2009.10

  the best neuronal sodium binding activity among the four groups of triazines evaluated. Derivatives 4a–4j blocked the sodium channels with IC50 values ranged from 4.0 to 14.7 μM. The result from this study showed that analogues of 2,4-diamino-1,3,5-triazines could be used as leads for the discovery of neuronal sodium channels blockers for managing central nervous system related disorders.

  神经元钠通道阻滞剂会干扰离子通量，并已用于治疗神经性疼痛，癫痫和脑缺血性疾病。在目前的研究中，合成了四组2,4-二氨基-1,3,5-三嗪衍生物，并研究了它们的神经元钠通道结合活性。在四组三嗪中，发现5-Aryl-1,3,5-triazaspiro [5.5] undeca-1,3-diene-2,4-diamines（4a - 4j）具有最佳的神经元钠结合活性。衍生物4a – 4j用IC 50阻断了钠通道值范围为4.0至14.7μM。这项研究的结果表明，2,4-二氨基-1,3,5-三嗪的类似物可以用作发现神经元钠通道阻滞剂以治疗中枢神经系统相关疾病的先导。
• Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies
  作者：Michele Tonelli、Stefano Espinoza、Raul R. Gainetdinov、Elena Cichero

  DOI：10.1016/j.ejmech.2016.10.058

  日期：2017.2

  murine and human TAAR1 agonists with potencies in nanomolar or low micromolar range, respectively. In particular, compounds BIG2 and BIG12-BIG14 were the most promising and they could be considered valuable lead compounds worthy of further investigations. In addition to the interest for developing more effective human TAAR1 ligands, the disclosed here potent murine TAAR1 agonists could offer suitable

  痕量胺（TAs）是内源性神经调节剂，在中枢神经系统（CNS）内的突触传递中起功能性作用，靶向痕量胺相关受体（TAARs）。从我们先前对TAAR1和TAAR5与非选择性配体3-碘胸腺嘧啶（T1AM）相互作用的计算研究开始，我们研究了27种基于双胍的衍生物在鼠和人TAAR1和鼠TAAR5受体上的功能活性，其中包括六种新合成的化合物。发现苯基（BIG2，BIG4，BIG8和BIG22）或苄基（BIG10-BIG16）双胍是选择性鼠类和人类TAAR1激动剂，分别具有纳米摩尔或低微摩尔范围的效力。特别是，化合物BIG2和BIG12-BIG14是最有前途的，可以认为它们是有价值的铅化合物，值得进一步研究。除了对开发更有效的人TAAR1配体的兴趣外，本文公开的强效鼠TAAR1激动剂还可以为研究TAAR1受体的药理学提供合适的工具。
• Biguanide derivatives, manufacturing method thereof, and disinfectants containing the derivatives
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0507317A2

  公开（公告）日：1992-10-07

  The invention presents a biguanide derivative or its salt expressed by a formula: (where R1 and R2 are as defined in Specification), or formula: (where A and R3 is as defined in specification). This biguanide derivative or its salt is preferably used as the effective amount of a disinfectant for humans, animals, medical appliances, etc.

  本发明提出了一种由式表示的双胍衍生物或其盐： (其中 R1 和 R2 如说明书中所定义），或式 (式中A和R3的定义见说明书）。这种双胍衍生物或其盐最好用作人、动物、医疗器械等有效量的消毒剂。
• Biguanide compound and use thereof
  申请人：ImmunoMet Therapeutics Inc.

  公开号：US10626085B2

  公开（公告）日：2020-04-21

  The present invention relates to a guanidine compound and a use thereof, and more specifically, to a guanidine derivative showing excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence; a preparation method thereof; and a pharmaceutical composition containing the same as an active ingredient. Compared to existing drugs, the guanidine derivative according to the present invention shows excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence even with small doses, and may thus be effectively used in preventing or treating various cancers such as uterine cancer, breast cancer, stomach cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, liver cancer, etc., inhibiting cancer cell proliferation and cancer metastasis.

  本发明涉及一种胍类化合物及其用途，更具体地说，涉及一种在抑制癌细胞增殖、癌症转移和癌症复发方面具有卓越效果的胍类衍生物；其制备方法；以及一种以其为有效成分的药物组合物。与现有药物相比，根据本发明的胍类衍生物即使剂量很小，也能显示出极佳的抑制癌细胞增殖、癌转移和癌症复发的效果，因此可有效用于预防或治疗各种癌症，如子宫癌、乳腺癌、胃癌、脑癌、直肠癌、大肠癌、肺癌、皮肤癌、血癌、肝癌等，抑制癌细胞增殖和癌转移。
• BIGUANIDE COMPOUND AND USE THEREOF
  申请人：Immunomet Therapeutics Inc.

  公开号：EP3222614B1

  公开（公告）日：2020-07-29